Skip to main navigation Skip to search Skip to main content

Integrating enhanced hepatitis C testing and counselling in research

  • Rebecca Winter
  • , Oanh Nguyen
  • , Peter Higgs
  • , Stuart Armstrong
  • , Duyen Duong
  • , My Thach
  • , Campbell Aitken
  • , Margaret Hellard

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Abstract The hepatitis C virus (HCV) affects over 170 million people worldwide. In Australia, over 225,000 people have been diagnosed with HCV infection with 13,000 infections reported annually; 90 are attributed to injecting drug use. Burnet Institute (BI) researchers have been studying the HCV epidemic since the virus was identified in 1989 including community based cohort studies (1990a??1995), numerous studies involvingVietnamese-Australian people who inject drugs (PWID) (1996a??2004) and social network studies (2000a??2002, 2005a??2007). Through this work the BI has developed a model of research practice for HCV and PWID, developed in recognition that much research relating to BBV infections a?? and HCV in particular a?? could be improved in terms of provision of test results to study participants. Our model endeavours to provide all participants with the highest quality HCV test results, delivered in accordance with best practice for pre- and post-test counselling by engaging participants in environments in which they are comfortable, building trust and rapport and being available throughout and beyond the research study. This paper will discuss the benefits and lessons learned over numerous studies in providing pre- and post-test counselling to PWID in an outreach capacity.
Original languageEnglish
Pages (from-to)66 - 70
Number of pages5
JournalInternational Journal of Drug Policy
Volume19
Publication statusPublished - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this